Introduction
============

Hepatocellular carcinoma (HCC), the incidence of which has been gradually increasing, is the fifth most common malignancy worldwide and the third most common type of cancer in the People's Republic of China.[@b1-ott-9-123],[@b2-ott-9-123] Moreover, it is estimated that 7.18% of the entire Chinese population is infected with hepatitis B virus (HBV).[@b3-ott-9-123],[@b4-ott-9-123] Until now, alpha-fetoprotein (AFP)-negative HCC has been difficult to diagnose, and there has been a lack of efficient and reliable diagnostic methods. AFP is a serum protein found at very low concentrations in the sera of normal humans, but is present at high concentrations in sera obtained from newborn humans. While AFP has been widely investigated as a biomarker for diagnosing HCC, it has proven to be a suboptimal diagnostic marker for HCC surveillance, as only a small proportion of individuals with HCC present with elevated AFP levels. AFPs comprise a group of heterogeneous glycoproteins and phytolectins, which contain different sugar moieties and display various features. One specific type of AFP, AFP-L3, binds to lectin *Lens culinaris* agglutinin and displays serum levels which are inconsistent with levels of AFP in human sera.[@b5-ott-9-123] Furthermore, the AFP-L3 isoform appears to be more specific than the total AFP level for diagnosing HCC.[@b6-ott-9-123] A retrospective study conducted by Shiraki et al[@b7-ott-9-123] demonstrated that nine (41%) of 21 liver cancer patients showed high concentrations of AFP-L3 at 12 months prior to an imaging diagnosis and that the proportion of AFP-L3 in total AFP was independent of the serum level of total AFP.[@b8-ott-9-123] If serum levels of AFP-L3 are highly specific for HCC, they could be used to screen individuals at high risk for HCC to achieve its early diagnosis and timely initiation of treatment.

Golgi protein 73, also called GP73, is a Golgi type II transmembrane protein. Kladney et al[@b9-ott-9-123] first described GP73 expression in biliary epithelial cells of normal livers, but found it was rarely expressed in hepatocytes. It has also been reported that GP73 expression is upregulated in HBV or HCV infection, alcoholic liver disease, or autoimmune hepatitis, and is found at strikingly high serum concentrations in HCC patients.[@b10-ott-9-123] Moreover, serum concentrations of GP73 in HCC patients are significantly higher than those in patients with liver cirrhosis.[@b11-ott-9-123] The sensitivity and accuracy of GP73 as indicators of HCC were shown to be 69% and 75%, respectively, and the area under the receiver operator characteristic (ROC) curve was greater than that of AFP (0.79 vs 0.61). Additionally, GP73 showed greater sensitivity than AFP for detecting early-stage HCC and a 57% sensitivity for detecting AFP-negative HCC, suggesting its value as a diagnostic marker for early-stage and/or AFP-negative HCC.[@b12-ott-9-123] A study of 535 patients with HCC or other chronic liver diseases found that all patients had high levels of GP73,[@b13-ott-9-123] suggesting its usefulness as a biomarker for early-stage HCC.

Materials and methods
=====================

Study populations
-----------------

Between September 2013 and June 2014, we recruited 50 AFP-negative HCC patients from the Qianfoshan Hospital in Shandong province to participate in this study. The inclusion criteria were as follows: 1) confirmed as primary HCC by color Doppler flow imaging or the results of a pathology examination and 2) an AFP level \<8.04 µg/L. Additionally, 30 patients (23 men and seven women; mean age 47 years, age range from 25 to 71) with other types of liver disorders (22 cases of cirrhosis, seven cases of chronic hepatitis B, and one case of severe hepatitis) were recruited from the same hospital. The diagnostic criteria used for chronic hepatitis B were as follows: 1) hepatitis B confirmed by pathology; 2) thickening of the spleen shown on imaging; and 3) a reversed albumin/globulin ratio. The diagnostic criteria for severe hepatitis included a plasma thromboplastin antecedent ≤40% and a serum total bilirubin level greater than tenfold normal. Liver cirrhosis was confirmed by B-mode ultrasound pathology findings. A list of the criteria used for diagnosing various types of liver disease is shown in [Tables 1](#t1-ott-9-123){ref-type="table"} and [2](#t2-ott-9-123){ref-type="table"}. Finally, we recruited a group of 50 healthy subjects (31 men and 19 women; mean age 42 years; range 20 to 68 years) from the same hospital to serve as controls. The 50 healthy subjects were required to meet the following criteria: 1) seronegative for AFP; and 2) no evidence of hepatitis, liver cirrhosis, a liver cyst, cholecyst, or a benign or malignant tumor. The protocol for this study was approved by the Qianfoshan Hospital Ethics Committee (NCT00000789), and all subjects provided a signed informed consent prior to enrollment.

Chemicals and instruments
-------------------------

The commercial kits used for detecting AFP-L3 and GP73 were purchased from Hotgen Biotech (Beijing, People's Republic of China). AFP detection kits and an ARCHITECT i2000SR automated chemiluminescence immunoassay analyzer were purchased from Abbott Laboratories (Abbott Park, IL, USA). A Zenyth 340 ELISA was purchased from Biochrom (Cambridge, UK).

Sampling
--------

A 4 mL sample of fasting venous blood was collected from each subject and stored at room temperature for 1 hour. After classification and labeling, the samples were transferred to storage at −20°C.

Detection of AFP-L3, GP73, and AFP
----------------------------------

The affinity adsorption method and immunosorbent assays were separately employed to detect the serum levels of AFP-L3 and GP73. AFP was detected by chemiluminescence. All detection methods were performed in strict accordance with instructions provided by the manufacturer of the detection kit. When using the kits, the critical values for AFP and GP73 were 8.04 and 55 µg/L, respectively, and the critical ratio for AFP-L3 as a percentage of total AFP was 10%.

Statistical analysis
--------------------

All statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA). Comparisons of AFP-L3- and GP73-positive rates between various groups were performed using the *χ*^2^ test. The sensitivity and accuracy of AFP-L3 and GP73 for detecting AFP-negative HCC were assessed by ROC curves. The confidence level was 95%.

Results
=======

Comparison of AFP-L3 in different groups
----------------------------------------

An affinity adsorption method was used to determine the serum level of AFP-L3 in all enrolled subjects. Among the 50 serum samples obtained from patients with a hepatocellular neoplasm, 25 were positive for AFP-L3. However, among the 30 samples obtained from patients with other liver diseases and 50 samples obtained from healthy subjects, only one sample from each group was positive for AFP-L3. Subjects with AFP-negative HCC had significantly higher serum levels of AFP-L3 compared to both non-HCC and healthy subjects (*P*\<0.01), while there was no significant difference in AFP-L3 levels between non-HCC patients and healthy subjects (*P*\>0.05). The outcomes of this analysis are shown in [Table 3](#t3-ott-9-123){ref-type="table"}.

Comparison of GP73 in different groups
--------------------------------------

The GP73-positive rates among patients with AFP-negative liver cancer, patients without liver cancer, and healthy subjects were 66%, 10%, and 0%, respectively. While patients with liver cancer had significantly higher serum levels of GP73 compared to non-HCC patients and healthy subjects, there was no significant difference in GP73 serum levels between non-HCC patients and healthy subjects. A comparison of GP73-positive rates in the three groups is shown in [Table 4](#t4-ott-9-123){ref-type="table"}.

Diagnostic utility of AFP-L3 and GP73
-------------------------------------

In the ROC curve analysis, the diagnostic accuracy of AFP-L3 and GP73 was evaluated. The maximum area under the curve for AFP-L3 in distinguishing AFP-negative HCC was 0.6094 (95% confidence interval, 0.5992--0.7996), and the sensitivity, specificity, and accuracy were 50%, 97.5%, and 79.2%, respectively. For GP73, the maximum area under the curve was 0.7811 (95% confidence interval, 0.7581--0.9241), and the sensitivity, specificity, and accuracy were 66%, 96.2%, and 84.6%, respectively. ROC curves for the diagnosis of HCC using AFP-L3 and GP73 are shown in [Figure 1](#f1-ott-9-123){ref-type="fig"} and the statistical outcomes in [Table 5](#t5-ott-9-123){ref-type="table"}.

Diagnostic utility of combined AFP-L3 and GP73 tests
----------------------------------------------------

If an assay for either AFP-L3 or GP73 showed a positive result, the outcome of the diagnosis was classified as positive. Among the 50 serum samples obtained from patients with a hepatocellular neoplasm, 20 samples were positive for both AFP-L3 and GP73, five samples were positive for AFP-L3 but negative for GP73, and ten were positive for GP73 but negative for AFP-L3. None of the 30 samples obtained from patients with other liver diseases were positive for both AFP-L3 and GP73; however, one sample was positive for AFP-L3 but negative for GP73, and one sample was positive for GP73 but negative for AFP-L3. Among the 50 samples obtained from healthy subjects, none were positive for both AFP-L3 and GP73, one sample was positive for AFP-L3 but negative for GP73, and no sample was positive for GP73 but negative for AFP-L3. The sensitivity, specificity, and accuracy achieved when using combined AFP-L3 plus GP73 assay results were 40%, 100%, and 76.9%, respectively. The outcomes of these analyses are shown in [Table 6](#t6-ott-9-123){ref-type="table"}.

Discussion
==========

A clinical diagnosis of HCC is easy if based on significantly increased serum AFP levels combined with definitive imaging results. However, AFP-negative HCC is not as easily diagnosed and becomes the focus of this study. A diagnosis of AFP-negative HCC depends largely on imaging results, which often shows defects such as a missed focus of disease in the right posterior portion of the liver adjoining the diaphragmatic dome by B ultrasound due to interference from air in the lung. Additionally, due to its high expense, a CT scan cannot be repeatedly performed in a short period. In recent years, numerous studies have been conducted to identify a diagnostic biomarker for AFP-negative HCC; however, all of the potential candidates have shown poor specificity and sensitivity. The clinical characteristics of AFP-negative HCC are as follows: 1) abdominal pain is the most common local symptom and manifests as a dull or stabbing pain in the right upper quadrant; 2) the abdominal pain can be intermittent or continuous; and 3) the pain is much severer at night and may radiate to the right shoulder and back. In this study, 50% of the subjects had abdominal pain. Our cohort of AFP-negative HCC patients included 17 males and three females thus supporting the notion described in previous reports that AFP-negative HCC is more prevalent in males than females.[@b14-ott-9-123]--[@b16-ott-9-123] This phenomenon might be mainly caused by higher rates of smoking and drinking among males.[@b14-ott-9-123] Ogden et al[@b17-ott-9-123] proposed that the HBx protein in HBV combines with p53 to alleviate p53-mediated repression of AFP gene expression, leading to overexpression of AFP. In our current study, up to 65% of AFP-negative HCC patients were infected with HBV, indicating AFP expression is influenced by a variety of factors. Izumi et al[@b18-ott-9-123] found that AFP-negative HCC patients had a significantly higher 5-year survival rate compared to AFP-positive patients. Additionally, the rates of positive rate for gamma-glutamyl transpeptidase (GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), adenosine deaminase (ADA), total bile acids (TBA), total bilirubin (TBIL), and prothrombin time (PT) in AFP-negative HCC patients were 45%, 30%, 50%, 15%, 30%, 10%, and 20%, respectively, and were notably lower than those in AFP-positive HCC patients indicating that values for GGT, ALT, AST, ADA, TBA, TBIL, and PT are not highly specific for identifying individuals with AFP-negative HCC.

GP73 is an early marker of HCC[@b12-ott-9-123] and is highly expressed only in individuals with acute or chronic liver disease, liver cirrhosis, or HCC. GP73 is thus regarded as a highly sensitive and specific biomarker for liver disease. When setting the critical value for AFP-L3 at 5% for AFP-negative patients (ie, \<20 µg/L indicating HCC), Toyoda et al[@b19-ott-9-123] found that AFP-L3 had 41.5% specificity and 85.1% sensitivity for diagnosing HCC. Moreover, AFP-L3 levels were found to be independent of total AFP levels, suggesting AFP-L3 as an independent diagnostic index, which is unrelated to levels of total AFP. When used for diagnosing HCC, AFP-L3 has higher specificity than total AFP, but similar sensitivity.[@b20-ott-9-123] While total serum AFP can be used to diagnose \~70% of HCC cases, \~30% of HCC cases are AFP-negative,[@b21-ott-9-123],[@b22-ott-9-123] leading to their missed or misdiagnosis. Thus, the accuracy of HCC diagnoses has been obviously increased by assessing multiple biomarkers.

Our results from evaluating serum levels of AFP-L3 and GP73 in the current study support the following conclusions: 1) compared with the non-HCC and healthy groups, the AFP-negative HCC group had a significantly higher percentage of individuals who tested positive for both AFP-L3 and GP73; 2) the sensitivity, specificity, and accuracy of AFP-L3 for diagnosing AFP-negative HCC were 50.0%, 97.5%, and 79.2%, respectively, while those of GP73 were 66.0%, 96.2%, and 84.6%, respectively; and 3) when using combined AFP-L3 and GP73 assay results to diagnosis AFP-negative HCC, the sensitivity, specificity, and accuracy were 40.0%, 100.0%, and 76.9%, respectively. Thus, sensitivity and accuracy achieved when using combined AFP-L3 and GP73 assay to diagnose AFP-negative HCC were higher than those achieved when using either assay result alone. Based on these data, we recommend using the combined assay for diagnosing HCC, as this method can aid in making an early, accurate, and differential diagnosis of AFP-negative HCC. A limitation of our study was that it included only 50 AFP-negative HCC patients because of low occurrence rate of HCC, and the etiology of HCC in Chinese population should also be considered, as it may not be the same as in other countries such as Japan, and the USA. Clinical trials with not only larger sample sizes and which include patient follow-up procedures but also populations from distinct regions must be conducted to confirm the value of using a combination of AFP-L3 and GP73 assay results for diagnosing AFP-negative HCC.
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###### 

Criteria used for diagnosing AFP-negative HCC in 50 patients

  Patient   Sex      Age   Admitting diagnosis                                                                                    Percussion pain in hepatic region
  --------- -------- ----- ------------------------------------------------------------------------------------------------------ -----------------------------------
  1         Male     58    Detected hepatic lesions after 2 days of physical examinations                                         No
  2         Male     63    Pruritus for 6 months; right abdominal pain and swelling                                               Mild
  3         Male     62    Hepatic lesions and enlargement for 2.5 months                                                         No
  4         Male     48    Hepatic lesions for 0.5 month                                                                          No
  5         Male     35    Right abdominal pain for 10 days                                                                       Yes
  6         Male     48    Right abdominal pain, swelling, nausea, and vomiting for \>1 month                                     Mild
  7         Male     32    Hepatic lesions detected after 7 days of physical examinations                                         No
  8         Male     41    Repeated abnormal liver function for 13 years; abdominal swelling for 0.5 month                        No
  9         Male     60    Chronic hepatitis B for 10 years; hepatic lesions detected after 7 days of physical examinations       No
  10        Male     43    Physical examination revealed right hepatic lesions                                                    No
  11        Male     77    Chest pain for 10 days                                                                                 Yes
  12        Male     56    Lower extremity edema and hypodynamia for \>10 days                                                    No
  13        Male     44    Hepatic lesions detected after 6 days of examinations                                                  No
  14        Male     65    Hepatic lesions detected after \>2 months of physical examinations                                     No
  15        Male     49    Diarrhea for \>1 month; black stools for 5 days                                                        Yes
  16        Male     32    Abdominal swelling for \>1 month                                                                       No
  17        Male     59    Abdominal pain and swelling for \>1 month                                                              No
  18        Male     66    Abdominal pain and swelling for \>10 days                                                              No
  19        Male     70    Abdominal swelling and hypodynamia for 1 week; a 1-day physical examination revealed hepatic lesions   No
  20        Male     62    Hepatic lesions detected after 7 days of physical examinations                                         No
  21        Male     42    Detected hepatic lesions after 2 days of physical examinations                                         No
  22        Male     53    Hepatic lesions detected after 10 days of physical examinations                                        No
  23        Male     65    Physical examination revealed right hepatic lesions                                                    No
  24        Male     44    Hepatic lesions detected after 7 days of physical examinations                                         Mild
  25        Male     32    Abdominal pain and swelling for \>20 days                                                              No
  26        Male     35    Abdominal pain and swelling for \>10 days                                                              No
  27        Male     64    Hepatic lesions detected after 7 days of physical examinations                                         No
  28        Male     63    Hepatic lesions detected after 7 days of physical examinations                                         No
  29        Male     55    Right abdominal pain, swelling, nausea, and vomiting for \>25 days                                     Mild
  30        Male     51    Hepatic lesions detected after 7 days of physical examinations                                         No
  31        Female   40    Abdominal pain and swelling for \>20 days                                                              No
  32        Female   31    Diarrhea for \>1 month; black stools for 5 days                                                        Yes
  33        Female   49    Abdominal pain and swelling for \>1 month                                                              No
  34        Female   53    Right abdominal pain, swelling, nausea, and vomiting for \>1 month                                     Mild
  35        Female   59    Abdominal pain and swelling for \>1 month                                                              No
  36        Female   61    Diarrhea for \>1 month; black stools for 5 days                                                        Yes
  37        Female   41    Abdominal pain and swelling for \>1 month                                                              No
  38        Female   67    Hepatic lesions detected after 7 days of physical examinations                                         No
  39        Female   58    Abdominal pain and swelling for \>15 days                                                              No
  40        Female   48    Hepatic lesions detected after \>1 month of physical examinations                                      No
  41        Female   47    Chest pain for 10 days                                                                                 Yes
  42        Female   36    Abdominal pain and swelling for \>20 days                                                              No
  43        Female   70    Right abdominal pain, swelling, nausea, and vomiting for \>1 month                                     Mild
  44        Female   36    Hepatic lesions detected after 14 days of physical examinations                                        No
  45        Female   56    Right abdominal pain, swelling, nausea, and vomiting for \>1 month                                     Mild
  46        Female   59    Hepatic lesions detected after 7 days of physical examinations                                         No
  47        Female   49    Hepatic lesions detected after \>1 month of physical examinations                                      No
  48        Female   46    Hepatic lesions detected after 20 days of physical examinations                                        No
  49        Female   34    Hepatic lesions detected after \>1.5 months of physical examinations                                   No
  50        Female   38    Hepatic lesions detected after 5 days of physical examinations                                         No

**Abbreviations:** AFP, alpha-fetoprotein; HCC, hepatocellular carcinoma.

###### 

Blood biochemical characteristics of the AFP-negative HCC patients

  Patient   ALT      AST      GGT      ADA     TBA     TBIL    PT      Test for hepatitis B
  --------- -------- -------- -------- ------- ------- ------- ------- ----------------------
  1         40.1     20.0     64.7↑    12.8    5.3     10.7    10.9    (−)
  2         46.5     43.7↑    69.4↑    42.5↑   47.7↑   7.9     11.0    Small three positive
  3         23.4     25.0     11.7     26.4↑   6.4     19.3    11.4    Small three positive
  4         44.5     50.1↑    106.9↑   20.7    44.4↑   13.8    11.7    Small three positive
  5         63.3↑    54.9↑    83.9↑    20.2    53.8↑   7.5     11.0    Small three positive
  6         28.6     24.5     69.5↑    13.8    2.8     8.8     10.1    (−)
  7         25.0     19.5     51.8     11.0    5.1     7.8     10.3    Great three positive
  8         105.8↑   72.8↑    191.7↑   18.7    49.4↑   28.5↑   13.3↑   Small three positive
  9         22.0     13.5     26.6     20.5    2.0     20.5    12.3↑   Small three positive
  10        374.2↑   458.8↑   95.6↑    25.0    11.7    18.4    12.0    Great three positive
  11        14.2     21.6     15.0     18.6    11.8    19.2    10.8    (−)
  12        63.8↑    87.6↑    19.6     18.1    16.9↑   33.0↑   16.6↑   Small three positive
  13        65.1↑    63.9↑    66.3↑    29.5↑   16.2↑   10.4    11.2    Great three positive
  14        67.0↑    47.1↑    257.5↑   12.6    11.5    10.0    12.0    Small three positive
  15        49.0     38.0     47.0     11.8    9.7     8.6     13.5↑   Small three positive
  16        15.7     23.3     10.8     8.8     1.8     7.6     9.7↓    (−)
  17        20.9     44.2↑    80.7↑    18.2    7.6     13.1    10.7    (−)
  18        23.9     24.2     24.1     22.0    2.1     15.1    10.1    (−)
  19        13.9     17.6     16.5     1.7     2.6     4.6↓    11.9    (−)
  20        41.0     47.8↑    303.0↑   17.3    5.2     16.6    10.6    (−)
  21        32.2     25.2     101      20.0    10.0    21.1    10.0    Small three positive
  22        14.3     46.6↑    52.2↑    16.9    11.9    26.0↑   11.0    Great three positive
  23        41.4↑    16.4     43.1     9.3     9.8     14.7    12.7↑   Small three positive
  24        55.9↑    28.5     16.9     14.8    15.3    16.9    14.1↑   (−)
  25        60.4↑    37.2↑    18.8     32.0    1.8     13.0    10.1    Small three positive
  26        35.7     47.3↑    32.3     10.0    5.4     18.1    8.7↓    Small three positive
  27        30.6     25.7     31.9     6.5     9.0     9.6     9.9     (−)
  28        28.8     35.8↑    43.5     21.1    7.5     4.9↓    11.5    Small three positive
  29        30.2     45.9↑    54.4↑    17.4    6.4     13.4    12.1    Great three positive
  30        15.3     24.0     62.8↑    18.8    10.6    16.8    13.7    Small three positive
  31        10.7     36.4↑    43.6     13.0    4.4     18.9    10.8    Small three positive
  32        15.1     16.3     41.7     12.4    6.8     19.2    9.9     Small three positive
  33        34.2     56.2↑    21.6     17.3    9.7     10.4    10.3    (−)
  34        39.5     46.1↑    35.5     15.4    12.4↑   11.1    11.9    (−)
  35        15.2     67.3↑    41.1     7.5     11.6    17.6    12.5↑   Small three positive
  36        28.7     43.5↑    10.3     11.0    20.1↑   20.3    11.0    Small three positive
  37        19.3     52.4↑    39.4     3.7     7.7     21.8    9.8     Small three positive
  38        20.7     16.6     28.7     9.9     6.6     25.1↑   10.1    (−)
  39        21.9     18.7     68.9↑    5.8     2.3     16.4    9.9     Small three positive
  40        17.6     19.8     56.5↑    30.0    1.4     10.9    10.1    Small three positive
  41        36.4     20.9     36.3     19.8    3.1     12.4    11.4    (−)
  42        68.8↑    64.9↑    41.4     12.7    1.6     16.6    12.0    (−)
  43        35.0     25.6     32.6     14.6    5.7     18.8    10.5    (−)
  44        102.2↑   23.4     69.5     25.0    6.6     17.0    16.1↑   (−)
  45        21.3     24.5     26.9     8.9     46.1↑   16.4    8.8↓    Small three positive
  46        38.4     14.6     18.4     24.3    5.7     7.7     11.7    (−)
  47        25.5     16.4     27.3     16.4    4.3     3.6↓    13.9↑   Small three positive
  48        21.7     19.3     109.1↑   30.0↑   6.1     8.5     11.1    Small three positive
  49        64.8↑    20.8     76.0↑    18.8    7.9     16.5    10.0    (−)
  50        11.9     36.7↑    58.9↑    17.9    4.7     38.0↑   9.9     Small three positive

**Notes:** Reference intervals of serum markers: ALT (7--40 U/L), AST (13--35 U/L), GGT (7--45 U/L), ADA (0--25 U/L), TBA (0--12 µmol/L), TBIL (5--24 µmol/L), PT (9.8--12.1 seconds), FB (1.8--3.5 g/L), APTT (22.7--31.8 seconds), and TT (14--21 seconds). Tests for hepatitis B (HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb): small three positive (HBsAg-positive, HBeAb-positive, and HBcAb-positive); great three positive (HBsAg-positive, HBeAg-positive, and HBcAb-positive). (↑), high level, (↓), low level.

**Abbreviations:** AFP, alpha-fetoprotein; HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; HBsAb, hepatitis B surface antibody; HBeAg, hepatitis B e antigen; HBeAb, hepatitis B e antibody; HBcAb, hepatitis B core antibody; FB, fibrinogen; APTT, activated partial thromboplastin time; TT, thrombin time; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; ADA, adenosine deaminase; TBA, total bile acids; TBIL, total bilirubin; PT, prothrombin time.

###### 

Comparison of AFP-L3-positive rates in the three AFP-negative groups

  Group           Patient   AFP-L3   *χ*^2^   *P*-value                                        
  --------------- --------- -------- -------- ------------------------------------------------ ------------------------------------------------
  HCC group       50        25       50.0     9.35[a](#tfn4-ott-9-123){ref-type="table-fn"}    0.002[a](#tfn4-ott-9-123){ref-type="table-fn"}
  Non-HCC group   30        1        3.3      13.28[b](#tfn5-ott-9-123){ref-type="table-fn"}   0.003[b](#tfn5-ott-9-123){ref-type="table-fn"}
  Healthy group   50        1        2.0      0.14[c](#tfn6-ott-9-123){ref-type="table-fn"}    0.032[c](#tfn6-ott-9-123){ref-type="table-fn"}

**Notes:**

HCC group compared with non-HCC group;

HCC group compared with healthy group;

non-HCC group compared with healthy group.

**Abbreviations:** AFP, alpha-fetoprotein; HCC, hepatocellular carcinoma.

###### 

Comparison of GP73-positive rates in the three AFP-negative groups

  Group           Patient   GP73   *χ*^2^       *P*-value                                        
  --------------- --------- ------ ------------ ------------------------------------------------ -------------------------------------------------
  HCC group       50        33     66 (33/50)   8.25[a](#tfn8-ott-9-123){ref-type="table-fn"}    0.009[a](#tfn8-ott-9-123){ref-type="table-fn"}
  Non-HCC group   30        3      10 (3/30)    23.35[b](#tfn9-ott-9-123){ref-type="table-fn"}   0.002[b](#tfn9-ott-9-123){ref-type="table-fn"}
  Healthy group   50        0      0            2.47[c](#tfn10-ott-9-123){ref-type="table-fn"}   0.036[c](#tfn10-ott-9-123){ref-type="table-fn"}

**Notes:**

HCC group compared with non-HCC group;

HCC group compared with healthy group;

non-HCC group compared with healthy group.

**Abbreviations:** AFP, alpha-fetoprotein; GP73, Golgi protein 73; HCC, hepatocellular carcinoma.

###### 

The performance of individual AFP-L3 and GP73 tests in diagnosing AFP-negative HCC

  Detection model   Sensitivity (%)   Specificity (%)   Accuracy (%)
  ----------------- ----------------- ----------------- ----------------
  AFP-L3            50.0 (25/50)      97.5 (78/80)      79.2 (103/130)
  GP73              66.0 (33/50)      96.2 (77/80)      84.6 (110/130)

**Abbreviations:** AFP, alpha-fetoprotein; GP73, Golgi protein 73; HCC, hepatocellular carcinoma.

###### 

The performance of combined AFP-L3 and GP73 assays for diagnosing AFP-negative HCC

  Detection model           Sensitivity (%)   Specificity (%)   Accuracy (%)
  ------------------------- ----------------- ----------------- ----------------
  AFP-L3 (+) and GP73 (+)   40.0 (20/50)      100 (80/80)       76.9 (100/130)
  AFP-L3 (+) and GP73 (−)   10.0 (5/50)       98.8 (79/80)      64.6 (84/130)
  AFP-L3 (−) and GP73 (+)   20.0 (10/50)      98.8 (79/80)      68.5 (89/130)
  AFP-L3 (−) and GP73 (−)   6.0 (3/50)        93.7 (75/80)      60.0 (78/130)

**Abbreviations:** AFP, alpha-fetoprotein; GP73, Golgi protein 73; HCC, hepatocellular carcinoma.
